Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Should both schistosomal and nonschistosomal variceal bleeders be disconnected?

View through CrossRef
AbstractSplenopancreatic disconnection (SPD) was conceived and implemented as a technical addition to distal splenorenal shunt (DSRS) to maintain its selectivity and preserve portal perfusion. The proposed hemodynamic and metabolic stability of hepatocytes after DSRS‐SPD should improve survival. In this nonrandomized study, 145 consecutive (Child A/B) variceal bleeders were electively subjected to selective shunt with DSRS in 93 and DSRS‐SPD in 52 patients. The 2 groups were similar before surgery with a mean follow up of 24±12 (DSRS) and 27±14 (DSRS‐SPD) months. DSRS‐SPD had an operative mortality of 3.8%. Postoperative pancreatitis occurred in 7.7% after DSRS‐SPD and 3.2% after DSRS alone, with schistosomal hepatic fibrosis representing 86% of morbid cases. Shunt patency was high and recurrent variceal hemorrhage was low in both groups. Clinical encephalopathy was significantly reduced after DSRS‐SPD (p<0.05). The addition of SPD significantly reduced both the incidence of chronic hyperbilirubinemia in the schistosomal patients (p< 0.05) and the difference between the changes in total serum bilirubin in all patients (p=0.001). Portal perfusion was preserved after DSRS‐SPD in all of the angiographically‐studied patients. The overall survival was 84% after DSRS and 88% after DSRS‐SPD. The schistosomal patients showed an incidence of 95% and 96% survival after DSRS and DSRS‐SPD, respectively. DSRS‐SPD was able to improve survival (92%) better than DSRS (77%) among well‐matched nonschistosomal patients. These data show: (1) DSRS‐SPD still has low operative mortality and a high patency rate with a low incidence of recurrent variceal hemorrhage, (2) DSRS‐SPD maintains portal perfusion, achieves better survival, and reduces the incidence of encephalopathy, especially in patients with nonalcoholic cirrhosis and mixed liver disease, (3) in the schistosomal population, DSRS‐SPD reduces the incidence of chronic hyperbilirubinemia but increases the risk of postoperative pancreatitis.
Title: Should both schistosomal and nonschistosomal variceal bleeders be disconnected?
Description:
AbstractSplenopancreatic disconnection (SPD) was conceived and implemented as a technical addition to distal splenorenal shunt (DSRS) to maintain its selectivity and preserve portal perfusion.
The proposed hemodynamic and metabolic stability of hepatocytes after DSRS‐SPD should improve survival.
In this nonrandomized study, 145 consecutive (Child A/B) variceal bleeders were electively subjected to selective shunt with DSRS in 93 and DSRS‐SPD in 52 patients.
The 2 groups were similar before surgery with a mean follow up of 24±12 (DSRS) and 27±14 (DSRS‐SPD) months.
DSRS‐SPD had an operative mortality of 3.
8%.
Postoperative pancreatitis occurred in 7.
7% after DSRS‐SPD and 3.
2% after DSRS alone, with schistosomal hepatic fibrosis representing 86% of morbid cases.
Shunt patency was high and recurrent variceal hemorrhage was low in both groups.
Clinical encephalopathy was significantly reduced after DSRS‐SPD (p<0.
05).
The addition of SPD significantly reduced both the incidence of chronic hyperbilirubinemia in the schistosomal patients (p< 0.
05) and the difference between the changes in total serum bilirubin in all patients (p=0.
001).
Portal perfusion was preserved after DSRS‐SPD in all of the angiographically‐studied patients.
The overall survival was 84% after DSRS and 88% after DSRS‐SPD.
The schistosomal patients showed an incidence of 95% and 96% survival after DSRS and DSRS‐SPD, respectively.
DSRS‐SPD was able to improve survival (92%) better than DSRS (77%) among well‐matched nonschistosomal patients.
These data show: (1) DSRS‐SPD still has low operative mortality and a high patency rate with a low incidence of recurrent variceal hemorrhage, (2) DSRS‐SPD maintains portal perfusion, achieves better survival, and reduces the incidence of encephalopathy, especially in patients with nonalcoholic cirrhosis and mixed liver disease, (3) in the schistosomal population, DSRS‐SPD reduces the incidence of chronic hyperbilirubinemia but increases the risk of postoperative pancreatitis.

Related Results

Effect of Anti-schistosomal Treatment on Schistosomal-specific Nephropathy
Effect of Anti-schistosomal Treatment on Schistosomal-specific Nephropathy
Abstract Twenty-one patients with schistosomal-specific nephropathy (18 nephrotics and three with non-nephrotic proteinuria) were given anti-schistosomal treatmen...
Significance of Interleukin-8 in Cystitis and Schistosomal Chronic Cystitis
Significance of Interleukin-8 in Cystitis and Schistosomal Chronic Cystitis
One of the important mediators of early inflammatory response in cystitis and an agent for attraction of neutrophils to the inflammation site is IL-8, in addition to its role in re...
Predictors of Non-Variceal Hemorrhage in a National Cohort of Patients with Chronic Liver Disease
Predictors of Non-Variceal Hemorrhage in a National Cohort of Patients with Chronic Liver Disease
Abstract Background: Non-variceal hemorrhage in patients with chronic liver disease (CLD) increases morbidity, mortality, and healthcare costs. There are limited data on r...
Carvidelol Vs Propanol for Secondary Prophylaxis of Variceal Hemorrhage in Liver Cirrhosis Patients
Carvidelol Vs Propanol for Secondary Prophylaxis of Variceal Hemorrhage in Liver Cirrhosis Patients
Propranolol and Carvedilol are the currently used medications for main prophylaxis of variceal bleeding. Objective: To investigate the efficacy of carvedilol vs propranolol for pre...
Efficacy of propranolol versus carvedilol in prophylaxis of variceal bleeding: Randomized clinical trial.
Efficacy of propranolol versus carvedilol in prophylaxis of variceal bleeding: Randomized clinical trial.
Objective: To compare the efficacy of carvedilol and propranolol for prophylaxis of variceal bleeding in cirrhotic patients. Study Design: Randomized Controlled Trial. Setting: Dep...

Back to Top